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Although guidelines recommend combining long-acting bronchodilators in COPD, data are
limited. We examined the clinical efficacy and safety of formoterol, tiotropium and the combi-
nation in patients with COPD.
Eight hundred and forty-seven patients with COPD (mean FEV1 52% predicted; FEV1/FVC 53%)
were randomized to receive one of the following four treatments for 24 weeks: formoterol
10 mg b.i.d. plus tiotropium 18 mg o.d.; formoterol 10 mg b.i.d.; tiotropium 18 mg o.d., or
placebo. The study was partially blinded (formoterol and placebo).
For the primary endpoint, FEV1 2 h post-dose after 24 weeks, there were small differences in
favour of the combination therapy versus formoterol (0.07 L, pZ 0.044) or tiotropium (0.06 L,
pZ 0.066). All three treatments were superior to placebo (p < 0.001). The combination was
statistically superior to monotherapy for: the primary endpoint (pZ 0.044 vs. formoterol);
FEV1 5 min after the first dose (p < 0.001) and at 12 weeks (p < 0.05 vs. tiotropium); and peak
expiratory flow averaged over the first 6 weeks (p < 0.001 vs. both). The three active treatments
were significantlymore effective than placebo for secondary endpoints: COPD-related ‘bad days’,
symptoms, use of rescue medication and peak expiratory flow, and aspects of health-related21 286 6451; fax: þ49 6421 286 8987.
0)69594 781.
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1512 C. Vogelmeier et al.quality of life. The overall incidence of adverse events was similar with all active treatments,
although COPD-related adverse events were more common with tiotropium.
Combined bronchodilator therapy may be a valuable treatment option for patients with COPD.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a leading
cause of morbidity and mortality world-wide, with a prev-
alence of more than 10% in the general population above
the age of 40 years.1 Bronchodilators are the mainstay of
the management of COPD. Current management guidelines2
recommend that patients with moderate or more severe
COPD should receive treatment with one or more long-
acting bronchodilators with different modes of action, with
the expectation that patients will benefit from increased
efficacy.
Formoterol (b2-agonist) and tiotropium (anticholinergic)
are long-acting bronchodilators with different mechanisms
of action. In addition to their bronchodilator effect, both
have been shown to improve health status and reduce
exacerbations in COPD patients.3e5 Formoterol has a fast
onset and a bronchodilator effect of approximately 12 h4,
while tiotropium has a 24-h bronchodilator effect and is
given once daily.6
The therapeutic potential of combining these two
bronchodilators in patients with COPD was first demon-
strated by Cazzola et al., both in stable disease7,8 and in
patients with acute exacerbations.9 Short-term studies
showed that combined therapy can improve airflow
obstruction and resting hyperinflation.10,11 More recently,
6-week studies have reported improved bronchodilation
with the combination versus salmeterol plus fluticasone,12
and improved bronchodilation, dyspnoea and rescue sal-
butamol use versus tiotropium alone.13
We set out to evaluate the efficacy of formoterol mono-
therapy and to determine whether the combination of for-
moterol twice daily with once-daily tiotropium would confer
benefits for a range of efficacy variables over a 24-week
treatment period. We were also interested to examine the
safety profiles of these approaches to treatment.Methods
Patients (inclusion/exclusion criteria)
The first patient was recruited in October 2004 and all
patients completed the study by November 2005.
The study included males and females with stable COPD14
aged 40 years at COPD onset and with a smoking history of
10 pack-years, forced expiratory volume in 1 second
(FEV1) < 70% of patient’s predicted normal value (and
1.00 L), and FEV1/forced vital capacity (FVC) < 70%. They
were to be symptomatic on at least 4 of 7 days prior to
randomization (symptom score >0 on diary card). The study
excluded patients who had a respiratory tract infection or
had been hospitalized for an acute exacerbation of COPD
within themonth prior to screening. Patients with a clinicallysignificant condition such as ischaemic heart disease that
might compromise patient safety or compliance were also
excluded.
The study was conducted in outpatient and specialist
clinics at 86 centres in Germany (30), Italy (19), Nether-
lands (9), Russian federation (9), Poland (7), Czech Republic
(4), Spain (4) and Hungary (4).
Study design
A screening period of up to 4 weeks included 2 weeks for
washout of disallowed medications and 2 weeks for eligi-
bility assessment and baseline evaluations. Patients
entered a 24-week treatment period and were randomized
to one of four treatments: (1) formoterol 10 mg twice daily
(b.i.d.) via multi-dose dry powder inhaler (MDDPI); (2)
placebo b.i.d. via MDDPI; (3) tiotropium 18 mg once daily
(o.d.) via the HandiHaler þ formoterol 10 mg b.i.d. via
MDDPI, and (4) tiotropium 18 mg o.d. (in the morning) via
the HandiHaler þ placebo b.i.d. via MDDPI. The dose of
formoterol in the MDDPI has previously been shown to be
similarly effective to the standard therapeutic dose of
12 mg administered via the single-dose device, the Aerolizer
(Novartis).15 The study was double-blind for treatment
comparisons (1) vs. (2) and (3) vs. (4) (MDDPI only), but not
for other comparisons as tiotropium was administered
open-label. Randomization was not stratified.
Salbutamol pMDI (2  100 mg/puff) was permitted as
rescue medication. Patients were asked not to use salbu-
tamol in the 8 h before a study visit. Patients could receive
inhaled corticosteroids (ICS) at a stable daily dose (any
patients receiving fixed combinations of ICS and b2-agonists
were switched to receive the same dose of ICS and on-
demand salbutamol).
Patients were instructed how to use the two inhaler
devices containing study medication and were observed at
each treatment visit to ensure correct inhalation tech-
nique, and re-trained if necessary. Patients were also
instructed on the correct use of their existing, concomitant
COPD medications.
Study assessments
Patients visited the clinic for efficacy and safety assess-
ments at baseline and at 6-week intervals until completion.
Spirometric assessments included FEV1 and FVC measured
at 5 min, 2 h and 3 h post-dose (the highest of three
acceptable manoeuvres were recorded for each time
point). Where possible, the same person evaluated a given
patient throughout the study. Spirometers were always
calibrated before measurements at each visit, and cali-
bration reports were stored.
Disease-specific quality of life (QoL) was assessed by the
St George’s Respiratory Questionnaire (SGRQ).16 Exercise
Formoterol and tiotropium in COPD 1513testing was by means of the 6-minute walking test, carried
out 3 h post-dose at the end of treatment. The walk test
was performed under standardized conditions,17 in a level
indoor corridor at least 33 m long with a 30 m distance
marked off, unimpeded by other corridor traffic, and under
trained supervision. Patients were asked to ‘walk as far as
you can in 6 minutes’.
Safety assessments included haematology and blood
chemistry, and patients were assessed regularly for vital
signs, electrocardiogram (ECG) and physical condition. All
adverse events (AEs) were recorded. Patients also
completed a daily diary card recording symptoms, peak
expiratory flow (PEF) and rescue salbutamol use.
Study endpoints
The primary efficacy outcome was FEV1 measured 2 h post-
dose after 24 weeks of treatment. Secondary efficacy
outcomes included: FEV1 and FVC at other time points
during the study (5 min, 2 and 3 h post-dose following the
first dose of treatment, and after 12 and 24 weeks of
treatment); COPD exacerbations; symptom scores, rescue
medication use and PEF; quality of life, and 6-minute
walking distance. According to the COPD exacerbations four
different variables were defined: (1) ‘bad days’ were days
with at least two symptoms recorded with a score of 2 or
more (breathlessness, cough, wheeze, amount of sputum
and colour of sputum were each recorded on a 0e3 scale);
(2) ‘COPD exacerbation days’ were days where two or more
of the same symptoms as above were recorded as being
worse than usual; (3) ‘COPD exacerbations requiring addi-
tional therapy’ were COPD-related AEs requiring additional
therapy, where COPD-related AEs were defined as AEs
coding to the preferred terms: COPD, COPD exacerbated,
cough, any term containing ‘dyspnoea’, lower respiratory
tract infection, chronic bronchitis, bronchospasm, bron-
chial obstruction and respiratory failure; and additional
therapy was any COPD therapy reported as being used to
treat a COPD exacerbation, other than rescue bronchodi-
lator; and (4) ‘COPD-related hospitalizations’. A treatment
plan was provided for acute COPD exacerbations detailing
a regimen of oral corticosteroids and/or antibiotics;
however, the treatment of exacerbations was ultimately at
the investigators’ discretion. Total daily symptom score and
rescue use were recorded on daily diary cards, along with
pre-medication morning PEF for the first 6 weeks of treat-
ment. The SGRQ was administered at baseline and
following 12 and 24 weeks of treatment. Six-minute walking
distance was assessed at baseline and following 24 weeks of
treatment. All endpoints were pre-specified.
Statistical analysis
Two previous studies of formoterol in COPD patients4,18 were
used to obtain an estimate of the between-patient standard
deviation of 0.30 L in FEV1 at 2 h post-dosing. To give 80%
power to detect a clinically relevant difference of 0.12 L
between formoterol and placebo19 as being statistically
significant at the 5% level using a two-sided test, approxi-
mately 100 patients per group were required. A separate
objective was to collect safety data for patients aged65 years and above, who (it was expected) would make up
about half the population patients.4,18 On this basis a sample
size of approximately 200 patients per group was chosen to
provide adequate power to test the primary objective and
reasonable power to test the secondary objectives, while
providing sufficient safety data in elderly patients.
FEV1 and FVC were analysed using an analysis of covari-
ance (ANCOVA) model including country, gender, revers-
ibility (<15% or 15%), baseline smoking status (current or
ex-smoker) and treatment as factors and baseline FEV1 as
covariate. PEF averaged over the first 6 weeks of treatment
was analysed using a similar ANCOVA model, with mean PEF
from the last 7 days of the screening period as the baseline
value. The percentages of COPD bad days and exacerbation
days were analysed using a similar ANCOVA model with the
baseline value being the average over the 7 days prior to
randomization. The number of patients with COPD exacer-
bations requiring additional therapy and those necessitating
hospitalization were analysed using the CochraneMantele
Haenszel test stratified by country. Mean daily total
symptom score (sum of scores for the five symptoms) and
mean rescue use were analysed by the van Elteren test
stratified by the baseline score. For QoL, the scores for three
domains (symptoms, activity, impacts) and the total score
were calculated and analysed using an ANCOVA model
similar to that used for the primary variable. The 6-minute
walking test was analysed using a similar model.
The intent-to-treat (ITT) population consisted of all
randomized patients who received at least one dose of
study medication. This population was used for efficacy and
safety analyses. All analyses were performed at the 5%
significance level (2-sided). Probability values were not
adjusted for multiple comparisons.
Results
Patients
Of 1081 patients screened, 847 were randomized. The
number of patients randomized per centre averaged 10
(range 1e32). The most common reasons that patients
failed screening were unacceptable medical history or
inappropriate spirometry evaluations, lung function being
inappropriate (FEV1 or FEV1/FVC > 70% of predicted or
FEV1 < 1.0 L) to qualify for study entry. The disposition of
patients and reasons for discontinuation are shown in
Table 1. Some patients encountered difficulties using the
MDDPI (used by all groups for delivering formoterol or
placebo) and 20% specifically reported a device-related
issue. Overall, 12e13% of patients discontinued early from
the active treatments, compared with 14.4% of placebo
patients. Details of the patients are shown in Table 2. All
but two patients were Caucasian.
During the treatment period, between 40.6% and 43.9% of
patients in each treatment group received treatment with
budesonide, fluticasone or beclometasone.
Bronchodilator effect
For the primary variable, FEV1 2 h post-dose after
24 weeks, there were numerical differences in favour of
Table 1 Patient disposition (n, %)
Formoterol Tiotropium Tiotropium þ formoterol Placebo Total
Screened 1081
Randomized 210 (100.0) 221 (100.0) 207 (100.0) 209 (100.0) 847 (100.0)
Completed 185 (88.1) 192 (86.9) 182 (87.9) 179 (85.6) 738 (87.1)
Patients discontinuing 25 (11.9) 29 (13.1) 25 (12.1) 30 (14.4) 109 (12.9)
Reason for discontinuing
Subject withdrew consent 12 (5.7) 11 (5.0) 11 (5.3) 11 (5.3) 45 (5.3)
Adverse event(s) 6 (2.9) 13 (5.9) 8 (3.9) 8 (3.8) 35 (4.1)
Protocol violation 4 (1.9) 3 (1.4) 3 (1.4) 6 (2.9) 16 (1.9)
Lost to follow-up 2 (1.0) 0 0 0 2 (0.2)
Administrative problems 1 (0.5) 0 3 (1.4) 1 (0.5) 5 (0.6)
Unsatisfactory therapeutic effect 0 2 (0.9) 0 3 (1.4) 5 (0.6)
Death 0 0 0 1 (0.5) 1 (0.1)
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CI) differences versus formoterol of 0.07 (0.00e0.14) L
(pZ 0.044) and versus tiotropium of 0.06 (0.00e0.13) L
(pZ 0.066). All three active treatments were significantly
more effective than placebo (p < 0.001), with estimated
mean differences in excess of the threshold for clinical
relevance of 0.12 L.19 FEV1 measurements after the first
dose and after 24 weeks are shown in Fig. 1. Results for FVC
(Fig. 2) closely followed those for FEV1.
COPD exacerbations
Combination therapy and monotherapy showed no clear
difference in the percentage of COPD-related bad days or
exacerbation days. Significantly fewer patients treated with
combination therapy and formoterol experienced exacer-
bations requiring additional treatment compared with those
receiving placebo (Table 3). Only a small number of patients
had COPD exacerbations requiring hospitalization, with no
significant between-group differences (Table 3).Table 2 Demographic and background characteristics of patien
Formoterol
(nZ 210)
Tio
(n
Age (yrs)
Mean (SD) 61.8 (8.8) 63.
Range 40e82 43e
Sex, n (%), male 159 (75.7) 175
Smoking history,
pack years
Mean (SD) 35.4 (18.0) 38.
Range 10e120 10e
Time since COPD diagnosis (yrs)
mean (SD) 7.0 (6.0) 6.9
Range 0e30 0e
FEV1, L: mean (SD) 1.52 (0.39) 1.5
FEV1, % predicted: mean (SD) 51.6 (10.6) 51.
FEV1/FVC (%): mean (SD) 54.6 (10.2) 54.
FEV1 reversibility (%)
a: mean (SD) 11.4 (12.9) 9.9
FEV1 reversible by 15%: n (%) 60 (28.6) 58
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ITT
a % change in FEV1 (absolute values) 30 min after inhaling salbutamSymptoms, use of rescue salbutamol and PEF
Average daily symptom scores and use of rescue medication
over the course of the study were statistically significantly
lower with combination and monotherapies versus placebo
(Table 4). Mean morning PEF during the first 6 weeks of
treatment was significantly greater with combination
therapy versus either monotherapy, with mean (95% CI)
differences of 11.0 (5.4e16.7) L/min vs. tiotropium and
10.6 (4.9e16.3) L/min vs. formoterol (both p < 0.001).
Disease-specific QoL
Differences between the three treatments relative to
placebo in the scores for the total and individual domains of
the SGRQ are shown in Fig. 3A. There were no significant
differences between combined therapy and either mono-
therapy (Fig. 3B). The scores showed a number of statisti-
cally significant improvements with active treatments
relative to placebo, concentrated in the symptomsts (ITT population)
tropium
Z 221)
Tiotropium þ formoterol
(nZ 207)
Placebo
(nZ 209)
4 (9.5) 62.6 (8.8) 62.5 (8.6)
83 43e82 42e82
(79.2) 164 (79.2) 162 (77.5)
6 (19.3) 37.9 (18.2) 40.1 (22.8)
120 10e120 8e150
(6.3) 7.2 (7.0) 6.7 (6.1)
35 0e33 0e35
0 (0.39) 1.48 (0.36) 1.50 (0.39)
6 (11.2) 50.4 (10.5) 51.1 (11.0)
4 (9.6) 53.2 (9.9) 53.5 (10.0)
(11.4) 11.0 (10.4) 11.4 (14.1)
(26.2) 62 (30.0) 60 (28.7)
, intention to treat.
ol 400 mg, measured at the screening visit.
Figure 1 FEV1 (SE) measured after (a) the first dose of study treatment and (b) 24 weeks of treatment with formoterol (B),
tiotropium (:), tiotropium þ formoterol (-) or placebo (). ***p < 0.001, **p < 0.01 vs. placebo; zp < 0.001, yp < 0.05 vs.
tiotropium, xp < 0.05 vs. formoterol.
Formoterol and tiotropium in COPD 1515component, which also reflected clinically relevant
improvements that were most marked with combined
treatment.
Walking distance
Estimated walking distances at the end of treatment,
adjusting for baseline distance, were 434 m for combined
treatment (nZ 179), 417 m for placebo (nZ 180), 425 mFigure 2 FVC (SE) measured after 24 weeks of treatment
with formoterol (B), tiotropium (:), tiotropium þ formoterol
(-) or placebo (). ***p < 0.001, **p < 0.01, *p < 0.05 vs.
placebo; yp < 0.05 vs. tiotropium.for formoterol (nZ 185) and 428 m for tiotropium
(nZ 189). The difference between combined therapy and
placebo was statistically significant (pZ 0.022); however,
the estimated difference of 17 m was below what is
commonly accepted as the minimal clinically important
difference, estimated to be 35e80 m.20,21
Safety
The overall incidence of adverse events was similar
between placebo and the other treatment groups.
Combined therapy did not appear to confer any increased
risk compared with individual therapies, either in the whole
population or the subgroup of patients aged 65 years
(Table 5). Similarly, there were no indications of safety
concerns affecting particular organ systems, including
cardiac disorders. Most adverse events (87e92% of events in
the active treatment groups) were mild or moderate in
severity.
One patient in the placebo group died during the study
after a fall. Of the serious adverse events, reported by 8e
10 patients in each active treatment group, three were
thought to be related to treatment: two cases of COPD
exacerbation (one tiotropium and one combined treat-
ment) and one case of tremor with formoterol. The case of
tremor was mild in severity but classed as serious because it
followed accidental mis-use of the inhaler, resulting in
overdosage. Thirty-three patients overall had adverse
events that led to withdrawal from the study; these were
fairly equally distributed, with a small excess of cases of
worsening COPD in the tiotropium treatment group. We also
collected data for ‘all COPD-related events’, including
additional related events such as cough, dyspnoea and
bronchospasm. COPD-related events were most common
with placebo (38 subjects; 18.2%), followed by tiotropium
(32 subjects; 14.5%), formoterol (24 subjects; 11.4%) and
Table 3 Percentage of COPD-related ‘bad days’ and ‘exacerbation days’ over 24 weeks of treatment (% of treatment days,
means and 95% CI), and number (%) of patients with COPD exacerbations requiring additional therapy and hospitalization (ITT
population)
Formoterol Tiotropium Tiotropium þ formoterol Placebo
COPD-related ‘bad days’ and ‘exacerbation
days’ (means and 95% CI)
Number of subjects 204 209 196 203
COPD-related bad days, % of treatment days 24.9a 25.6a 26.3b 33.9
20.8e29.0 21.5e29.7 22.2e30.5 29.8e38.1
COPD exacerbation days, % of treatment days 2.4c 3.3 3.3 4.7
1.0e3.8 1.9e4.7 1.9e4.7 3.4e6.1
Patients with COPD exacerbations requiring
additional therapy and hospitalization
Number of subjects 210 221 207 209
COPD exacerbations requiring additional
therapy, n (%)
17 (8.1)d 23 (10.4) 13 (6.3)e 30 (14.4)
COPD exacerbations requiring hospitalization, n (%) 1 (0.5) 5 (2.3) 3 (1.4) 3 (1.4)
CI: confidence intervals. ITT: intention to treat.
a p  0.001 vs. placebo (ANCOVA).
b pZ 0.004 vs. placebo (ANCOVA).
c pZ 0.007 vs. placebo (ANCOVA).
d pZ 0.041 vs. placebo (CochraneManteleHaenszel test).
e pZ 0.006 vs. placebo (CochraneManteleHaenszel test).
1516 C. Vogelmeier et al.combined treatment (23 subjects; 11.1%). Such events were
serious or led to premature discontinuation from the study
in 7 (3.3%) subjects taking placebo, 9 (4.1%) taking tio-
tropium, 4 (1.9%) taking combined treatment and 4 (1.9%)
taking formoterol.
Laboratory values and vital signs showed no statisti-
cally significant or clinically relevant changes with
treatment; only isolated individual abnormal values or
changes were seen. Results for serum potassium showed
no significant differences between treatments at the end
of the study: compared with placebo, differences wereTable 4 Symptom scores and rescue medication use averaged o
treatment period (ITT population)
No. of patients
with post-
treatment data
Averaged daily total sym
score, median (range)
Baseline Tre
Formoterol 206 5.00 4.2
(0.00e13.00) (0.0
Tiotropium 212 5.00 4.5
(0.57e13.57) (0.0
Tiotropium þ
formoterol
201 5.43 4.8
(0.00e11.29) (0.0
Placebo 206 5.14 5.2
(0.43e12.43) (0.0
ITT: intention to treat. Total daily symptom scoreZ sum of scores fo
each scored on a 0e3 scale where 0Z no symptoms.
a p  0.001 vs. placebo (van Elteren test stratified by baseline valu
b p < 0.01 vs. placebo (van Elteren test stratified by baseline value
c p < 0.05 vs. placebo (van Elteren test stratified by baseline value0.02, 0.00 and 0.07 mmol/L for the formoterol, tio-
tropium and combined treatments, respectively. There
was an unexpected shift to above-normal plasma potas-
sium levels in 4e5% of subjects receiving formoterol (with
or without tiotropium). b2-agonists are known to decrease
plasma potassium via skeletal muscle cell potassium
uptake;22,23 however, owing to artefacts several indi-
vidual readings were known to be unreliable, and mean
values did not differ significantly.
ECG measurements showed no differences in QTc
interval between groups in mean values; abnormal valuesver baseline (the second week of screening) and the 24-week
ptom Averaged daily number of puffs
of rescue medication, median (range)
atment Baseline Treatment
9b 2.43 1.30b
0e12.04) (0.00e8.86) (0.00e9.96)
0b 1.71 0.67a
4e13.72) (0.00e15.14) (0.00e10.57)
4c 2.14 0.57a
1e15.00) (0.00e10.29) (0.00e8.00)
0 2.00 1.77
0e11.61) (0.00e9.29) (0.00e10.71)
r breathlessness, cough, wheeze, amount and colour of sputum,
e).
).
).
Figure 3 SGRQ scores (total and individual components)
recorded after 24 weeks of treatment. (a) With formoterol
(B), tiotropium (:) or tiotropium þ formoterol (-), including
last (12-week) values for patients who did not complete the
study: the graph shows differences between active and
placebo treatment groups (ITT population). Negative values
indicate improved quality of life relative to placebo.
***p < 0.001, **p < 0.01, *p < 0.05 vs. placebo. Dashed line:
minimum clinically important difference. (b) Differences
between combined therapy versus tiotropium () and versus
formoterol (>). Bars represent 95% CI.
Formoterol and tiotropium in COPD 1517or changes occurred with similar frequencies in the active
treatment groups and were not more frequent with
combination treatment.
Discussion
It is generally acknowledged that bronchodilators confer
a range of benefits in patients with COPD, in whom the
presence or absence of an acute bronchodilator response
(reversibility) as assessed by FEV1 does not predict long-
term benefits such as symptom improvement and exercise
tolerance, or even the future response to bronchodila-
tors.2,24e26 In this study, the benefits of long-acting bron-
chodilators in COPD were demonstrated in their efficacy
relative to placebo in terms of bronchodilator effect (FEV1
2 h post-dose, primary variable).
The combination of formoterol and tiotropium provided
an improvement over either monotherapy. The size of this
difference was less than has been previously observed in
studies in patients with more severe COPD,10,11,13 and inexacerbating COPD patients.9 While it is possible that the
bronchodilator effects of combined therapy may be greater
in patients with more severe COPD, a 52-week study by
Aaron et al., again in a more severe group of patients than
in the present study, showed no additional effect on lung
function (pre-bronchodilator FEV1) with the addition of
salmeterol to tiotropium, compared with tiotropium
alone.27 This is one of the first studies to study combination
therapy in patients with relatively less severe COPD.
Another recent study in patients with moderate COPD (50%
were reversible) found superior bronchodilation with for-
moterol plus tiotropium compared with salmeterol plus
fluticasone after 6 weeks, although other clinical outcomes
were not explored.12
While the primary goal of the present study was to assess
the bronchodilator effects and safetydespecially in the
elderlydof combined bronchodilator therapy, an additional
aim was to define different characteristics of transient
COPD deteriorations, or exacerbations. It is well known that
the healthcare utilization-based definition of exacerbations
can be misleading in a multinational study such as ours.
Thus, we looked for four different categories for deterio-
ration, defined variously as symptom-based and health care
utilization-based. While the descriptions of exacerbations
used in this study preceded the unified definition recently
set down in the GOLD guidelines,2 the definition of ‘bad
days’ and ‘exacerbation days’ was not only a pre-specified
endpoint in the study but was also sufficiently rigorously
defined so as to be independent of national differences.
Defining exacerbations in terms of healthcare utilization
alone may otherwise undermine the reliability of the find-
ings of multinational studies such as ours, conducted in
countries with very different health care systems and
accessibility.
Long-acting bronchodilator combination treatment
showed similar effects irrespective of the symptom- and
intervention-based definitions of exacerbations, respec-
tively. Formoterol in particular had a significant effect on
both COPD-related ‘bad days’ and ‘exacerbation days’,
representing the milder end of the spectrum of exacerba-
tions assessed in this study. Similar results have been
reported elsewhere.4,18 In one study,28 mild exacerbations
(days with high use of rescue medication) were reduced by
a highly significant 55% with formoterol versus placebo in
patients with moderate-to-severe COPD, while severe
exacerbations were not affected.
The effectiveness of long-acting bronchodilators in
controlling the symptoms of COPD is also reflected in the
improvements in symptoms, use of rescue bronchodilator,
PEF and quality of life (particularly the symptoms domain)
in all treatment arms of the present study. We did not
observe the same differential effects of combined therapy
on symptoms and rescue use reported by Tashkin et al. in
a more severe group of patients, although the combination
arm demonstrated an 8-unit decrease in the symptoms
domain.13 It is possible that the advantages of combination
therapy would be more apparent in more severe stages of
COPD. In the study by Aaron et al.,27 salmeterol plus tio-
tropium did not significantly reduce the proportion of
patients with exacerbations (the primary endpoint) versus
tiotropium monotherapy, although the incidence rate ratio
for severe exacerbations requiring hospitalization was 0.83.
Table 5 Most frequent adverse events (affecting 2% or more of combination treatment group) (n, %) (ITT population) in (a) all
patients and (b) patients aged 65 years
Formoterol Tiotropium Tiotropium þ formoterol Placebo
(a) All patients (nZ 210) (nZ 221) (nZ 207) (nZ 209)
Any adverse event 72 (34.3) 79 (35.7) 70 (33.8) 82 (39.2)
COPD worsening 20 (9.5) 28 (12.7) 16 (7.7) 34 (16.3)
Nasopharyngitis 15 (7.1) 11 (5.0) 13 (6.3) 11 (5.3)
Cough 3 (1.4) 5 (2.3) 5 (2.4) 4 (1.9)
(b) Patients aged 65 years (nZ 83) (nZ 107) (nZ 93) (nZ 85)
Any adverse event 30 (36.1) 35 (32.7) 35 (37.6) 40 (47.1)
COPD worsening 11 (13.3) 11 (10.3) 9 (9.7) 17 (20.0)
Nasopharyngitis 5 (6.0) 5 (4.7) 5 (5.4) 2 (2.4)
Back pain 1 (1.2) 0 2 (2.2) 2 (2.4)
Cough 1 (1.2) 2 (1.9) 3 (3.2) 4 (4.7)
Hypertension 1 (1.2) 3 (2.8) 2 (2.2) 2 (2.4)
Shoulder pain 1 (1.2) 0 2 (2.2) 1 (1.2)
Oedema peripheral 0 0 3 (3.2) 0
Productive cough 0 0 2 (2.2) 0
ITT, intention to treat.
1518 C. Vogelmeier et al.Although the latter reduction was not significant, the
results raise the possibility that combination bronchodilator
therapy may provide the most benefit, in terms of exacer-
bations, in patients with more advanced stages of disease.
Further investigation in populations with clearly defined
disease severity is required to clarify this possibility.
A potential limitation of this study arises from the only
partially blinded nature of the study design, since a tio-
tropium placebo was not available and the formoterol
versus tiotropium comparison therefore had to be open-
label. Thus, patients knew if they were taking tiotropium,
although not whether they were receiving formoterol or
placebo from the MDDPI. Only the formoterol versus
placebo and combination versus tiotropium comparisons
were double blind, thus limiting the strength of the
conclusions that can be drawn from other comparisons.
Another limitation could be that the 6 months’ duration
of the study did not allow exacerbations to be assessed
reliably.29 However, exacerbations were not the primary
focus of the study; several long-term studies have assessed
exacerbations reliably. Patients’ continued use of inhaled
corticosteroids may have attenuated any signal in respect
of exacerbations. However, discontinuation prior to study
inclusion prevents a reliable assessment of exacerbation
frequency.30
In the present study, comparisons between combination
and single therapies showed some statistically significant
(although clinically small) differences in bronchodilator
effect (FEV1) and lung function (mean morning PEF).
Significant differences were not apparent for exacerba-
tions, QoL and walking distance. However, the combined
approach tended to provide the most marked improvement
relative to placebo for many variables, including walking
distance and the symptoms component of quality of life.
The study may have been underpowered to detect some of
the differences between combination and monotherapy.
The combined bronchodilator approach did not appear
to increase the burden of adverse events compared withindividual treatments, either in the whole population or in
the subgroup of older patients. This is an important
consideration in a population of patients who are typically
elderly and may suffer a range of co-morbidities that
increase their vulnerability to, for example, adverse
cardiac effects of treatment. It is reassuring that specific
investigations of this effect with formoterol31 or tio-
tropium32 show little cause for undue concern.
The present study confirms the efficacy and safety of
long-acting bronchodilators in patients with moderate
COPD. The addition of formoterol to tiotropium treatment
conferred small advantages in terms of the early broncho-
dilator effect, lung function measured at trough effect
(PEF, pre-bronchodilator) or post-bronchodilator (FEV1),
and an indication of fewer exacerbations requiring addi-
tional treatment, although this was not statistically signif-
icant. The safety profile of the combination is comparable
to either single therapy and may even be preferable in
terms of fewer reports of COPD as an adverse event than
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